| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cristiano S Moura, Albert Etingin, Luck Lukusa, Harminder Singh, Neeraj Narula, Laura E Targownik, Yvette Leung, Petros Zezos, Beata Polewiczowska-Nowak, Waqqas Afif and Sasha Bernatsky |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Canadian Institutes for Health Research |
DES-156672 |
|
| Corresponding Author |
Sasha Bernatsky, MD, PhD, Professor, Centre for Outcomes Research and Evaluation, The Research Institute of the McGill University Health Centre, 5252 Boul de Maisonneuve Ouest, Montreal H4A 3S5, Quebec, Canada. sasha.bernatsky@mcgill.ca |
| Key Words |
Inflammatory bowel disease; Adalimumab; Infliximab; Biosimilars; Emergency department visits; Hospitalization; Clinical remission |
| Core Tip |
Biologic therapies are effective for many people with inflammatory bowel disease, but they are expensive. Biosimilars are equivalent, lower-cost versions of biologic originators, yet real-world evidence comparing their effectiveness remains limited. We analyzed data from a Canadian multicenter registry including adults living with Crohn’s disease or ulcerative colitis, initiating originator or biosimilar. Outcomes of interest were remission and health care resource use. We found no clear differences in remission, hospitalizations, or emergency visits between the two groups. These findings support broader adoption of biosimilars and provide reassurance to patients and clinicians regarding their comparable effectiveness. |
| Publish Date |
2026-02-27 08:35 |
| Citation |
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World J Gastroenterol 2026; 32(9): 114580 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i9/114580.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i9.114580 |
